Mammography
Conditions
Brief summary
Women who attend for their screening mammogram will be recalled if an abnormality is detected on the screening mammogram. Calcifications account for 20% of the women recalled to second stage screening. Currently there is no effective imaging tool to determine if the calcifications are cancer or not. Therefore, 90% of women will be subjected to a biopsy. 25-30% of the biopsies will show cancer. Contrast enhanced spectral mammography (CESM) is where contrast is given and then a mammogram performed. The theory is that high risk DCIS and invasive cancers have an increased blood supply and will therefore enhance more than benign lesions within the breast. If CESM can identify calcifications that are cancerous then we maybe able to reduce the number of women who have benign biopsies. This is patient focused as women would not require a biopsy and be able to be reassured at the same visit. This is also a cost-saving for the Trust by reducing unnecessary biopsies. This also supports the findings of the Marmot review by aiming to reduce harm by over-diagnosis.
Interventions
DIAGNOSTIC_TESTContrast enhanced spectral mammography (CESM)
Contrast enhanced spectral mammography (CESM) will be undertaken in addition to routine practice. CESM is a specialist mammography test that aims to 'highlight' areas of concern within the breast in more detail than a standard mammogram. The difference between CESM and a standard mammogram (x-ray of the breast) is the use of a special dye (called contrast medium) that is injected into the veins before the mammogram images are taken. The contrast enhanced images give more detailed information to the breast radiologists (expert doctors trained to analyse breast imaging).
Sponsors
The Leeds Teaching Hospitals NHS Trust
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
50 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Recalled for second stage screening due to microcalcifications on the mammogram 2. Renal function is within normal limits 3. No known allergies to contrast 4. Able to give informed consent
Exclusion criteria
1. Known allergy to contrast 2. Renal impairment 3. Unable to provide informed consent 4. Having radioactive iodine treatment for hyperthyroidism
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of benign biopsies | 3 years | Total number of benign biopsies identified whilst undergoing CESM. |
Countries
United Kingdom
Contacts
Primary ContactNisha Sharma, MBChB; MRCP; FRCR; M
Outcome results
None listed